NO donors with anticancer activity

Expert Opinion on Therapeutic Patents

Volumn 12, Issue 6, 2002, Pages 819-826

  Jia, Qiang ^a   Janczuk, Adam J ^a   Cai, Tingwei ^a   Xian, Ming ^a   Wen, Zhong ^a   Wang, Peng George ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Anticancer; Antitumour; Nitric oxide (NO); Nitric oxide donor

Indexed keywords

1 [N METHYL N [6 (N METHYLAMMONIOHEXYL)AMINO]DIAZEN 1 IUM 1,2 DIOLATE; 1,1 DIETHYL 2 NITROSOHYDRAZINE; 1,2 DIAMINOCYCLOHEXANE; AMMONIUM DERIVATIVE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ARGININE; CALCIUM ION; CISPLATIN; FRUCTOSE 1 N ACETYL S NITROSOPENICILLAMINE; GAMMA INTERFERON; GLUCOSE 2 N ACETYL S NITROSOPENICILLAMINE; GLYCERYL TRINITRATE; HYDRAZINE DERIVATIVE; LINSIDOMINE; MORPHOLINE DERIVATIVE; N ACETYL S NITROSOPENICILLAMINE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; ORGANIC NITRATE; OXYGEN RADICAL; PACLITAXEL; PLATINUM COMPLEX; PLATINUM DERIVATIVE; SPERMINE; SPERMINE DERIVATIVE; THYMIDINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CANCER RESEARCH; CARCINOGENESIS; CARDIOTOXICITY; CONTROLLED STUDY; DRUG STRUCTURE; GASTROINTESTINAL TOXICITY; HUMAN; MOUSE; NONHUMAN; PATENT; PATHOLOGY; REVIEW; STRUCTURE ACTIVITY RELATION; TUMOR PROMOTION;

EID: 0036075801     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.12.6.819     Document Type: Review

References (75)

1. Nitric oxide: A unique endogenous signaling molecule in vascular biology
2. Endothelium-derived relaxing factor: Discovery, early studies, and identification as nitric oxide
3. Nitric oxide physiology, pathophysiology and pharmacology
4. Antioxidants and the bioactivity of endothelium-derived nitric oxide
5. Nitric oxide and platelet-mediated hemostasis
6. The action and interactions of nitric oxide in solid tumor
7. Nitric oxide. I. Physiological chemistry of nitric oxide and its metabolites: Implications in inflammation
8. Nitric oxide in excitable tissues: Physiological roles and disease
9. Endogenous nitric oxide synthesis: Biological functions and pathophysiology
10. Nitric oxide synthases: Roles, tolls, and controls
11. Nitric oxide synthases: Structure, function and inhibition
12. S-nitrosothiols: A class of nitric oxide-donor drugs
13. Gas-phase oxidation of nitric oxide: Chemical kinetics and rate constant
14. Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide
15. Role of nitric oxide in macrophage antimicrobial activity
16. Apoptosis and necrosis: Two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures
17. Nitric oxide induces necrotic but not apoptotic cell death in oligodendrocytes
18. Nitric oxide-induced cytotoxicity: Involvement of cellular resistance to oxidative stress and the role of glutathione in protection
19. Murine cytotoxic activated macrophages inhibit aconitase in tumor cells. Inhibition involves the iron-sulfur prosthetic group and is reversible
20. The surprising life of nitric oxide
21. Nitric oxide in cells
22. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells
23. Nitric oxide synthesis contributes to IL-2-induced antitumor responses against intraperitoneal Meth A tumor
24. Nitric oxide inhibits ornithine decarboxylase by S-nitrosylation
25. Exogenous nitric oxide inhibits proliferation of cultured vascular endothelial cells
26. Multistage carcinogenesis in mouse skin
27. Nitric oxide modulates expression of matrix metalloproteinase-9 in rat mesangial cells
28. Nitric oxide inhibition selectively increases matrix metalloproteinase-9 activation in vitro by rat aortic smooth muscle cells
29. p53 cell cycle control and apoptosis: Implication for cancer
30. Nitric oxide donor SNAP induces apoptosis in smooth muscle cells through cGMP-independent mechanism
31. Nitric oxide-induced apoptosis in tumor cells
32. Nitric oxide-induced apoptosis in human leukemic lines requires mitochondrial lipid degradation and cytochrome c release
33. Activation of nitric oxide synthase gene for inhibition of cancer metastasis
34. Nitric oxide synthase activity and expression in human colorectal cancer
35. Significance of nitric oxide in carcinogenesis, tumor progression and cancer therapy
36. Role of nitric oxide in tumor progression: Lessons from experimental tumors
37. Role of nitric oxide in carcinogenesis and tumor progression
38. Role of nitric oxide in tumour progression with special reference to a murine breast cancer model
39. Nitric oxide and cancer
40. Role of macrophage-derived nitric oxide in target cell injury
41. The multifaceted roles of nitric oxide in cancer
42. Diazeniumdiolates: Pro- and antioxidant applications of the 'NONOates'
43. Nitric oxide donors: Chemical activities and biological applications
44. Nitric oxide (NO)-related pharmaceuticals: Contemporary approaches to therapeutic NO modulation
45. Nitric oxide donors
46. Nitric oxide donors-current trends in therapeutic applications
47. Immunoregulatory effects of L-arginine and therapeutical implications
48. Effect of L-arginine on the retention of macrophage tumoricidal activity
49. Changes in energy metabolism and X-ray sensitivity in murine tumors by the nitric oxide donor SIN-1
50. Glyco-S-nitrosothiols, a novel class of NO donor compounds
51. Current trends in the development of nitric oxide donors
52. Glyco-S-nitrosothiols: Sugar-SNAP, a new type of nitric oxide donor
53. In vitro cytotoxicity of glyco-S-nitrosothiols. A novel class of nitric oxide donors
54. Antitumor activity of a novel glyco-nitric oxide conjugate in ovarian carcinoma
55. Targeting nitric oxide to cancer cells: Cytotoxicity studies of glyco-S-nitrosothiols
56. Nitroglycerin: A NO donor inhibits TPA-mediated tumor promotion in murine skin
57. Biotransformation and cytotoxic properties of NO-donors on MCF7 and U251 cell lines
58. Complexes of NO with nucleophiles as agents for the controlled biological release of nitric oxide. Vasorelaxant effects
59. Nitric oxide/nucleophile complexes inhibit the in vitro proliferation of A375 melanoma cells via nitric oxide release
60. Differential inhibitory effects of three nitric oxide donors on ornithine decarboxylase activity in human colon carcinoma cells
61. The hypoxic cell: A target for selective cancer therapy-eighteenth
62. Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression
63. Nitric oxide-mediated regulation of chemosensitivity in cancer cells
64. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy
65. Vascular and interstitial barriers to delivery of therapeutic agents in tumors
66. Nitric oxide and cGMP regulate endothelial permeability and F-actin distribution in hydrogen peroxide-treated endothelial cells
67. Nitriglycerin-mediated vasorelaxation is modulated by endothelial calcium-activated potassium channels
68. Pharmacological reactivity of neoplastic and non-neoplastic associated neovasculature to vasoconstrictors
69. Effects of the disintegrin eristostatin on individual steps of hematogenous metastasis
70. Rationale for development of platinum analogs
71. Cisplatin and nitric oxide have synergistic antitumor activity in cP resistant human melanoma cells
72. Nitric oxide improves cisplatin cytotoxicity in head and neck squamous cell carcinoma
73. Structural significance of the benzoyl group at the C-3′-N position of paclitaxel for nitric oxide and tumor necrosis factor production by murine macrophages
74. Structural significance of the acyl group at the C-10 position and the A ring of the taxane core of paclitaxel for inducing nitric oxide and tumor necrosis factor production by murine macrophages
75. Relationship between the structure of taxol and other taxanes on induction of tumor necrosis factor-α gene expression and cytotoxicity